United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 10/11/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/627,439	07/25/2003	Kenneth T. Richardson	017380-000313US	5370
20350 75	590 10/11/2006	•	EXAM	INER
TOWNSEND AND TOWNSEND AND CREW, LLP			MARSCHEL, ARDIN H	
TWO EMBARCADERO CENTER EIGHTH FLOOR		ART UNIT	PAPER NUMBER	
SAN FRANCISCO, CA 94111-3834			1614	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/627,439	RICHARDSON ET AL.			
Office Action Summary	Examiner	Art Unit			
	Ardin Marschel	1614			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of the second period for reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	I. sely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
2a) ☐ This action is FINAL . 2b) ☒ This					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims		,			
4)⊠ Claim(s) 29, 30 and 49-69 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 20,30 and 49-69 are subject to restric	tion and/or election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
	•				
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) L Interview Summary (Paper No(s)/Mail Da	•			
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Pa				

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claim 29, drawn to a layered tablet with an immediate-release layer and a sustained release layer with a specific list of active ingredients, classified in Class 424, subclass 472.
- II. Claim 30, drawn to a layered tablet with an immediate-release layer and a sustained release layer with a specific list of active ingredients, classified in Class 424, subclass 472.
- III. Claims 49-61, drawn to a unit dosage form being a vaginal dosage form with active ingredients, classified in class 424, subclass 430. If this Group is elected then the below set forth specie election is also required.
- IV. Claims 62-69, drawn to a unit dosage form being a topical dermal dosage form with active ingredients, classified in class 424, subclass 430. If this Group is elected then the below set forth specie election is also required.

SPECIE ELECTION REQUIREMENT FOR GROUPS III or IV:

This application contains claims directed to the following patentably distinct species of the claimed invention:

The sets of active ingredients optionally with amounts thereof each result in differing treatment results due to differences in said ingredients. For Groups III or IV, applicant is required under 35 U.S.C. 121 to elect a single disclosed specie of a specific set of ingredients with associated amounts for the active ingredients in order to start

Application/Control Number: 10/627,439

Art Unit: 1614

examination for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 49 and 55 (Group III) and claim 62 (Group IV) are generic to the above Species. These species result in different treatment active ingredients being delivered with their corresponding distinct effects that need to be separately examined and searched thus supporting the undue search burden if they are examined together.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/627,439

Art Unit: 1614

The inventions are distinct, each from the other because:

The distinctness between the species has been described above.

Inventions of Groups I, II, III, and IV are directed to related, but distinct, inventions. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the inventions of Groups I, II, III, and IV have different design, mode of operation, function, and effect due to being directed to different layered tablet forms with pharmakinetics related to immediate and sustained release portions as well as different treatment effects directed to differing treatment formulations therein. Therefore, an undue search burden would be required to search them together thus supporting this restriction requirement.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1614

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the Central PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CFR § 1.6(d)). The Central PTO Fax Center number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., Supervisory Patent Examiner, AU 1614, whose telephone number is (571)272-0718. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instrument Examiner, Florence Patterson, whose telephone number is (571)272-0544.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

September 30, 2006

ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER

Andi V. Marshel 9/30/06